{
    "clinical_study": {
        "@rank": "97567", 
        "arm_group": [
            {
                "arm_group_label": "Myomectomy, rectal  Misoprostol", 
                "arm_group_type": "Experimental", 
                "description": "25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation."
            }, 
            {
                "arm_group_label": "Myomectomy, Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this research work  is to assess the effect of using single preoperative dose of\n      rectal misoprostol in abdominal myomectomy operations on blood loss, duration of the\n      operation and possible operative complications"
        }, 
        "brief_title": "Impact of Misoprostol on Blood Loss In Myomectomy Operations", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Leiomyoma", 
        "condition_browse": {
            "mesh_term": [
                "Leiomyoma", 
                "Myofibroma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a randomized, double-blind, controlled study that will be conducted in Ain\n      Shams University Maternity Hospital.\n\n      A total of 50 women scheduled to undergo myomectomy for symptomatic uterine myoma will be\n      included in this study after taking their consent for this clinical trial after full\n      explanation of the trial.\n\n      The total of 50 included patients will be divided into two groups: Group A (Study group;):\n      will Include 25 patients undergoing myomectomy operation will receive two tablets of\n      misoprostol (400 mcg) rectally two hours before the operation.Group B (Control group): will\n      Include 25 patients undergoing myomectomy operation will not receive misoprostol before the\n      operation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Premenopausal patients aged between 35 to 50 years old.\n\n          -  Five or less symptomatic uterine myomas .\n\n          -  Maximum diameter of the largest myoma is 6 cm .\n\n          -  All myomas are subserous or intramural.\n\n          -  Uterine size less than 24 weeks pregnancy\n\n        Exclusion Criteria:\n\n          -  History of previous surgery.\n\n          -  Allergy to Misoprostol.\n\n          -  Hypertension.\n\n          -  Cardiac and Pulmonary diseases.\n\n          -  Patients who have bleeding disorders.\n\n          -  Anemia (Hb < 10g %).\n\n          -  Chronic endocrine or metabolic diseases such as Diabetes.\n\n          -  Obesity (body mass index > 30 kg/m2).\n\n          -  Cases that will require intraoperative conversion of myomectomy to hysterectomy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061657", 
            "org_study_id": "AIN-1111-MM"
        }, 
        "intervention": [
            {
                "arm_group_label": "Myomectomy, rectal  Misoprostol", 
                "description": "25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation", 
                "intervention_name": "Misoprostol", 
                "intervention_type": "Drug", 
                "other_name": "Cytotec"
            }, 
            {
                "arm_group_label": "Myomectomy, Placebo", 
                "description": "Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.", 
                "intervention_name": "Placebo( for misoprostol)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Misoprostol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "Ain Shams University, Maternity Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1 Study of Misoprostol in Reducing Intraoperative Bleeding in Myomectomy Operations", 
        "overall_contact": {
            "email": "dr_m.hafeez@hotmail.com", 
            "last_name": "Mohamed A. Abdel-hafeez, Lecturer", 
            "phone": "002 01005016222"
        }, 
        "overall_contact_backup": {
            "email": "draknaggar@yahoo.com", 
            "last_name": "Ahmed M. Elnaggar, Lecturer", 
            "phone": "0044 7797790230"
        }, 
        "overall_official": [
            {
                "affiliation": "Ain Shams University", 
                "last_name": "Abd El Mgeed I. Abd El Mgeed, Professor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Ain Shams University", 
                "last_name": "Mohamed S. Ali, Professor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Ain Shams University", 
                "last_name": "Mohamed A. Abdel-Hafeez, Lecturer", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ain Shams University", 
                "last_name": "Mina A. Yacoup, Fellow", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ain Shams University", 
                "last_name": "Ahmed M. Elnaggar, Lecturer", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Higher Education", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "intraoperative blood loss", 
            "safety_issue": "No", 
            "time_frame": "time from peritoneum opening till its closure  around (1 Hour)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061657"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ain Shams University", 
            "investigator_full_name": "Dr.Ahmed Elnaggar", 
            "investigator_title": "DR", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Ain Shams University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ain Shams University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}